share_log

The Total Return for West Pharmaceutical Services (NYSE:WST) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

The Total Return for West Pharmaceutical Services (NYSE:WST) Investors Has Risen Faster Than Earnings Growth Over the Last Five Years

在過去五年中,西方製藥服務(紐約證券交易所代碼:WST)投資者的總回報增長速度快於收益增長
Simply Wall St ·  05/23 18:30

It might be of some concern to shareholders to see the West Pharmaceutical Services, Inc. (NYSE:WST) share price down 11% in the last month. But in stark contrast, the returns over the last half decade have impressed. In fact, the share price is 190% higher today. To some, the recent pullback wouldn't be surprising after such a fast rise. Of course, that doesn't necessarily mean it's cheap now.

上個月,西部製藥服務公司(紐約證券交易所代碼:WST)的股價下跌了11%,這可能會引起股東的擔憂。但與之形成鮮明對比的是,過去五年的回報給人留下了深刻的印象。實際上,今天的股價上漲了190%。對某些人來說,在如此快速的上漲之後,最近的回調並不奇怪。當然,這並不一定意味着它現在很便宜。

While the stock has fallen 4.9% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

儘管該股本週下跌了4.9%,但值得關注長期來看,看看股票的歷史回報是否是由基礎基本面推動的。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。評估公司情緒變化的一種有缺陷但合理的方法是將每股收益(EPS)與股價進行比較。

Over half a decade, West Pharmaceutical Services managed to grow its earnings per share at 21% a year. This EPS growth is reasonably close to the 24% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. In fact, the share price seems to largely reflect the EPS growth.

在過去的五年中,西部製藥服務成功地將其每股收益增長到每年21%。每股收益的增長相當接近股價年均增長24%。這表明,在那段時間內,公司周圍的市場情緒沒有太大變化。實際上,股價似乎在很大程度上反映了每股收益的增長。

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

該公司的每股收益(隨着時間的推移)如下圖所示(點擊查看確切數字)。

earnings-per-share-growth
NYSE:WST Earnings Per Share Growth May 23rd 2024
紐約證券交易所:WST 每股收益增長 2024 年 5 月 23 日

It might be well worthwhile taking a look at our free report on West Pharmaceutical Services' earnings, revenue and cash flow.

可能值得一看我們關於西部製藥服務收益、收入和現金流的免費報告。

What About Dividends?

分紅呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for West Pharmaceutical Services the TSR over the last 5 years was 194%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報 (TSR) 和 股價回報。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。我們注意到,西部製藥服務在過去5年的股東總回報率爲194%,好於上述股價回報率。因此,該公司支付的股息提高了 股東回報。

A Different Perspective

不同的視角

While the broader market gained around 30% in the last year, West Pharmaceutical Services shareholders lost 1.7% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 24% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. If you would like to research West Pharmaceutical Services in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

儘管去年整體市場上漲了約30%,但西部製藥服務的股東損失了1.7%(甚至包括股息)。即使是優質股票的股價有時也會下跌,但我們希望在過於感興趣之前看到企業基本指標的改善。好的一面是,長期股東賺了錢,在過去的五年中,每年增長24%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。如果你想更詳細地研究西方製藥服務,那麼你可能需要看看內部人士是否在買入或賣出該公司的股票。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找獲利投資的人來說,這份最近進行內幕收購的被低估公司的免費清單可能只是入場券。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論